Last reviewed · How we verify

lignocaine+dexamethasone

Aligarh Muslim University · FDA-approved active Small molecule

Lignocaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and swelling at the injection site.

Lignocaine provides local anesthesia by blocking sodium channels in nerve fibers, while dexamethasone reduces inflammation and swelling at the injection site. Used for Local anesthesia with anti-inflammatory effect for injection or infiltration, Pain relief with reduced inflammation in localized conditions.

At a glance

Generic namelignocaine+dexamethasone
SponsorAligarh Muslim University
Drug classLocal anesthetic + corticosteroid combination
TargetVoltage-gated sodium channels (lignocaine); glucocorticoid receptor (dexamethasone)
ModalitySmall molecule
Therapeutic areaPain management, Anesthesia, Inflammation
PhaseFDA-approved

Mechanism of action

Lignocaine is a local anesthetic that inhibits sodium influx into nerve cells, preventing depolarization and blocking pain signal transmission. Dexamethasone is a corticosteroid that suppresses inflammatory responses by inhibiting phospholipase A2 and reducing prostaglandin and cytokine production. Together, this combination provides both anesthetic and anti-inflammatory effects for localized pain and inflammation management.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: